Guo Zhaoxin, Hu Xiaolin, Lv Renguang, Zhang Yongzhen, Meng Liwei, Liu Zhaoxu, Yan Lei
Department of Urology, Qilu Hospital of Shandong University, Jinan, 250012 Shandong, China.
Department of Endocrinology, Jinan Central Hospital, Jinan, 250033 Shandong, China.
Dis Markers. 2022 Aug 17;2022:4506350. doi: 10.1155/2022/4506350. eCollection 2022.
To investigate the effect of bicalutamide combined with docetaxel on the levels of prostate-specific antigen (PSA) in serum and vascular endothelial growth factor (VEGF) in patients with advanced prostate carcinoma (PCa).
The clinical data of 103 patients with advanced PCa at our hospital between Feb. 2020 and Feb. 2021 were retrospectively analyzed, the 90 of whom screened by inclusion and exclusion criteria were finally chosen as research objects. They were divided into a control group and an experimental group according to the order of admission, with 45 cases in each group. The control group was treated with conventional treatment, while the experimental group underwent the combination of bicalutamide and docetaxel, and the clinical indices of the two groups were compared.
After treatment, the serum indices in the experimental group were remarkably lower than those in the control group ( < 0.001), with remarkably lower incidence of toxic and side effects ( < 0.05) and higher Expanded Prostate Cancer Index Composite (EPIC) scores ( < 0.001) in the experimental group than in the control group.
The implementation of bicalutamide combined with docetaxel in patients with advanced PCa is effective in reducing the inflammatory expression and improving quality of life and has a higher safety profile. Compared with conventional treatment, this method is of high application value, and further studies will help establish a better solution for such patients.
探讨比卡鲁胺联合多西他赛对晚期前列腺癌（PCa）患者血清前列腺特异性抗原（PSA）水平及血管内皮生长因子（VEGF）的影响。
回顾性分析我院2020年2月至2021年2月期间103例晚期PCa患者的临床资料，最终将90例经纳入和排除标准筛选的患者作为研究对象。按入院顺序将其分为对照组和试验组，每组45例。对照组采用常规治疗，试验组采用比卡鲁胺联合多西他赛治疗，比较两组的临床指标。
治疗后，试验组血清指标显著低于对照组（<0.001），试验组毒副作用发生率显著低于对照组（<0.05），扩展前列腺癌指数综合评分（EPIC）显著高于对照组（<0.001）。
晚期PCa患者采用比卡鲁胺联合多西他赛治疗可有效降低炎症表达、提高生活质量，且安全性更高。与传统治疗相比，该方法具有较高的应用价值，进一步研究将有助于为此类患者建立更好的治疗方案。
